286 related articles for article (PubMed ID: 21138381)
1. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration.
Swan D; Long J; Carr O; Flanagan J; Irish H; Keating S; Keaveney M; Lambert J; McCormick PA; McKiernan S; Moloney J; Perry N; Cullen W
AIDS Patient Care STDS; 2010 Dec; 24(12):753-62. PubMed ID: 21138381
[TBL] [Abstract][Full Text] [Related]
2. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.
Treloar C; Newland J; Rance J; Hopwood M
J Viral Hepat; 2010 Dec; 17(12):839-44. PubMed ID: 20070504
[TBL] [Abstract][Full Text] [Related]
3. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
4. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B
Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734
[TBL] [Abstract][Full Text] [Related]
5. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
Doab A; Treloar C; Dore GJ
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
[TBL] [Abstract][Full Text] [Related]
6. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
7. Where are people being tested for anti-HCV in England? Results from sentinel laboratory surveillance.
Brant LJ; Hurrelle M; Balogun MA; Klapper P; Ramsay ME;
J Viral Hepat; 2008 Oct; 15(10):729-39. PubMed ID: 18637078
[TBL] [Abstract][Full Text] [Related]
8. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
[TBL] [Abstract][Full Text] [Related]
9. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.
Myles A; Mugford GJ; Zhao J; Krahn M; Wang PP
Can J Gastroenterol; 2011 Mar; 25(3):135-9. PubMed ID: 21499577
[TBL] [Abstract][Full Text] [Related]
10. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
[TBL] [Abstract][Full Text] [Related]
11. Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study.
Souliotis K; Agapidaki E; Papageorgiou M; Voudouri N; Contiades X
Int J Equity Health; 2017 Jun; 16(1):101. PubMed ID: 28615023
[TBL] [Abstract][Full Text] [Related]
12. Management of HCV and HIV infections among people who inject drugs.
Grebely J; Tyndall MW
Curr Opin HIV AIDS; 2011 Nov; 6(6):501-7. PubMed ID: 22001894
[TBL] [Abstract][Full Text] [Related]
13. "It gives me a sense of belonging": providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group.
Woolhouse S; Cooper E; Pickard A
Int J Drug Policy; 2013 Nov; 24(6):550-7. PubMed ID: 23860471
[TBL] [Abstract][Full Text] [Related]
14. Experience of hepatitis C testing among injecting drug users in Sydney, Australia.
Day CA; White B; Thein HH; Doab A; Dore GJ; Bates A; Holden J; Maher L
AIDS Care; 2008 Jan; 20(1):116-23. PubMed ID: 18278622
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ
Int J Drug Policy; 2015 Oct; 26(10):992-8. PubMed ID: 25697089
[TBL] [Abstract][Full Text] [Related]
16. Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users.
Coupland H; Day C; Levy MT; Maher L
Health Promot J Austr; 2009 Dec; 20(3):234-40. PubMed ID: 19951245
[TBL] [Abstract][Full Text] [Related]
17. Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow.
McDonald SA; Hutchinson SJ; Cameron SO; Innes HA; McLeod A; Goldberg DJ
Int J Drug Policy; 2012 Sep; 23(5):353-7. PubMed ID: 22421553
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a general practice based hepatitis C virus screening intervention.
Anderson EM; Mandeville RP; Hutchinson SJ; Cameron SO; Mills PR; Fox R; Ahmed S; Taylor A; Spence E; Goldberg DJ
Scott Med J; 2009 Aug; 54(3):3-7. PubMed ID: 19728405
[TBL] [Abstract][Full Text] [Related]
19. The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception.
Safo SA; Batchelder A; Peyser D; Litwin AH
Harm Reduct J; 2015 Jun; 12():20. PubMed ID: 26092261
[TBL] [Abstract][Full Text] [Related]
20. The impact of injecting drug use status on hepatitis C-related referral and treatment.
Stoové MA; Gifford SM; Dore GJ
Drug Alcohol Depend; 2005 Jan; 77(1):81-6. PubMed ID: 15607844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
